Alcon’s Growth Trajectory: Positive Survey Insights and Product Launches Drive Buy Rating
TipRanks (Mon, 6-May 8:25 AM ET)
Alcon Publishes Agenda for 2024 Annual General Meeting
Business Wire (Sun, 7-Apr 5:59 PM ET)
Vivity, the World's Leading EDOF IOL, Reaches One Million Milestone
Business Wire (Wed, 6-Mar 8:00 AM ET)
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
Business Wire (Tue, 27-Feb 4:30 PM ET)
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Alcon trades on the NYSE stock market under the symbol ALC.
As of May 6, 2024, ALC stock price climbed to $80.28 with 223,424 million shares trading.
ALC has a beta of 0.93, meaning it tends to be less sensitive to market movements. ALC has a correlation of 0.24 to the broad based SPY ETF.
ALC has a market cap of $40.12 billion. This is considered a Large Cap stock.
Last quarter Alcon reported $2 billion in Revenue and $.70 earnings per share. This fell short of revenue expectation by $-8 million and exceeded earnings estimates by $.02.
In the last 3 years, ALC stock traded as high as $88.78 and as low as $55.21.
The top ETF exchange traded funds that ALC belongs to (by Net Assets): DFIV, DFIC, DFAI, DFAX, JHMD.
ALC has underperformed the market in the last year with a price return of +10.0% while the SPY ETF gained +27.7%. However, in the short term, ALC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.1% vs +4.4% return in SPY. But in the last 2 weeks, ALC shares have been beat by the market, returning +0.9% compared to an SPY return of +3.9%.
ALC support price is $78.63 and resistance is $80.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALC stock will trade within this expected range on the day.